OncRef

Clinical Trial: NCT03164616

Study of Durvalumab + Tremelimumab With Chemotherapy or Durvalumab With Chemotherapy or Chemotherapy Alone for Patients With Lung Cancer (POSEIDON).

Status:

ACTIVE NOT RECRUITING

Phase:

Phase 3

Lead Sponsor:AstraZeneca
Information Provided By:AstraZeneca
Last Update Posted:2026-03-13

Study Overview

Brief Summary

This is a randomized, open-label, multi-center, global, Phase III study to determine the efficacy and safety of durvalumab + tremelimumab combination therapy + Standard of care (SoC) chemotherapy or durvalumab monotherapy + SoC chemotherapy versus SoC chemotherapy alone as first line treatment in patients with metastatic non small-cell lung cancer (NSCLC) with tumors that lack activating epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) fusions.

Official Title

A Phase III, Randomized, Multi-Center, Open-Label, Comparative Global Study to Determine the Efficacy of Durvalumab or Durvalumab and Tremelimumab in Combination With Platinum-Based Chemotherapy for First-Line Treatment in Patients With Metastatic Non Small-Cell Lung Cancer (NSCLC) (POSEIDON)

Conditions

Non Small Cell Lung Cancer NSCLC

Intervention / Treatment

  • Drug: Durvalumab
  • Drug: Tremelimumab
  • Drug: Abraxane + carboplatin
  • Drug: Gemcitabine + cisplatin
  • Drug: Gemcitabine + carboplatin
  • Drug: Pemetrexed + carboplatin
  • Drug: Pemetrexed + cisplatin

Other Study ID Numbers

  • D419MC00004
  • 2017-000920-81
  • 2017

Start Date (Actual)

2017-06-01

Primary Completion Date (Actual)

2021-03-12

Study Completion Date (Estimated)

2027-11-15

Enrollment (Actual)

1186

Study Type

Interventional

Phase

Phase 3